# CORTEX BOARDROOM — 3-DAY STRATEGIC SUMMIT
## "Swarm Intelligence, Market Prediction & the Healthtech Inflection Point"
### March 17–19, 2026 | Classified: Board Eyes Only

---

> **Stimulus:** MiroFish — a swarm intelligence engine scaling to 1M autonomous agents for real-world prediction — has just become GitHub's #1 trending project globally (28K stars, $4.1M seed in 24 hours). The healthtech market is crossing $300B in 2026. The question before the Cortex Boardroom is not whether AI will reshape health — it has. The question is **where exactly we sit in that reshaping, and what we must build next.**

---

## PARTICIPANTS

| Seat | Handle | Role | Summit Focus |
|------|--------|------|--------------|
| 1 | ARCHIE | CTO & Principal Architect | Technical architecture, stack evolution, swarm integration |
| 2 | PAUL | CPO & UX Strategist | Product surface, user value, feature prioritization |
| 3 | VICTOR | CSO & Enterprise Sales Director | GTM, pricing, competitive positioning |
| 4 | GORDON | CFO & Unit Economics Analyst | Unit economics, compute cost, runway implications |
| 5 | RUTH | CLO & Regulatory Guardian (**supreme veto**) | SaMD, LGPD, ANVISA, consent architecture |
| 6 | ELENA | CMO & Clinical Evidence Guardian (**supreme veto**) | Clinical safety, biomarker integrity, simulation fidelity |
| 7 | CYRUS | CISO & Security Architect (**supreme veto**) | Swarm data security, agent isolation, PII in simulation |
| 8 | QUINN | QA Lead & Test Automation | Validation methodology for agentic systems |

**Facilitator:** ARCHIE (default orchestrator per ROUTER.md)

---

---

# DAY 1 — INTELLIGENCE BRIEFING & THREAT MAPPING
## "What MiroFish signals about the future we're already in"

---

### OPENING — [ACTIVATING: ARCHIE — CTO & Principal Architect]

*The boardroom convenes at 0800. ARCHIE opens with the intelligence brief.*

Colleagues. I'm going to be direct: MiroFish is not a toy. It is a signal that the simulation-centric paradigm has crossed the viability threshold. Let me walk through what it actually is technically, then I'll hand each seat the floor.

**Technical brief on MiroFish:**

MiroFish uses a five-stage pipeline: Graph Construction → Environment Setup → Simulation Execution → Report Generation → Deep Interaction. It ingests "seed material" — a news event, a policy draft, a financial signal — and constructs a GraphRAG knowledge graph. It then populates a simulation environment with agents carrying independent personalities, long-term memory (via Zep Cloud), and behavioral logic. Those agents interact freely. Emergent behavior produces prediction reports.

The OASIS framework underneath it (CAMEL-AI) scales to one million agents running 23 social actions simultaneously. A single developer plugged it into Polymarket, ran 2,847 digital humans before each trade, and reported $4,266 profit over 338 trades. That is not a proof of concept. That is a new category of intelligence tool in production.

**The question for our codebase:** We are building a clinical decision support system with biomarker tracking, Manchester triage logic, and patient population management. MiroFish is architecturally a prediction engine built on multi-agent simulation. **These two domains are not separate. They are convergent.** The first healthtech team to apply swarm simulation to patient population prediction — at the cohort and individual level — will own a defensible moat that no LLM fine-tune can replicate overnight.

*ARCHIE delegates to the room.*

---

### SESSION 1.1 — MARKET INTELLIGENCE DEEP DIVE

**[DELEGATING TO: VICTOR — CSO & Enterprise Sales Director]**

*VICTOR stands, paces.*

Let's talk about the battlefield. Here's what the market intelligence tells us as of March 2026:

**The Numbers that Matter:**

The global healthtech digital health market is now **over $300 billion**. The LATAM sub-market we're specifically targeting — Brazil, Mexico, Colombia — is expected to hit $5.6 billion in 2026, growing at a CAGR the rest of the world envies. Bionexo just acquired Tasy from Philips for €161M. That is not an acquisition; that is Philips waving the white flag on regional hospital IT and handing the territory to local specialists. That is our territory.

**The Competitive Texture:**

85% of all generative AI healthcare spend is flowing to **startups**, not incumbents. That means Epic, Cerner, and Philips are bleeding share to purpose-built, agentic solutions. The ambient scribes category alone generated $600M in 2025 — and it's a 2.4x year-over-year climb. Abridge owns 30% of that category. Ambience owns 13%. Nuance's DAX Copilot has 33% but it's a legacy trajectory.

The category we should be watching most closely: **clinical decision support with embedded agentic reasoning**. This is not yet won. The Keragon, Qure.ai, and Hippocratic AI cohort are attacking narrow wedges — imaging, administrative, chatbots. Nobody has built the full-stack clinical intelligence layer for LATAM's regulatory and linguistic context. That's the white space.

**Where MiroFish changes the GTM calculus:**

If we can predict patient cohort behavior — hospitalizations, drug adherence, deterioration trajectories — before clinical events occur, we shift from a "decision support tool" to a "prediction-driven care operating system." That changes our pricing model from per-seat SaaS to outcome-linked contracts. Hospital systems in Brazil will pay dramatically more for a platform that reduces ICU bed-days than for one that improves documentation speed.

*VICTOR yields to ELENA.*

---

### SESSION 1.2 — CLINICAL OPPORTUNITY MAPPING

**[DELEGATING TO: ELENA — CMO & Clinical Evidence Guardian]**

*ELENA speaks with precision.*

I want to establish what swarm simulation can and cannot do in our clinical context — because the temptation will be to overpromise, and that is a path I will veto.

**What swarm simulation CAN credibly do for us:**

1. **Cohort-level epidemiological prediction.** If we train agents on anonymized patient population data — demographic profiles, comorbidity patterns, triage histories — we can simulate how a patient cohort evolves over 30, 90, and 180 days. This is not individual clinical diagnosis. This is population health management, which is a defensible clinical use case with much lower regulatory friction.

2. **Drug adherence modeling.** Agents with behavioral profiles (age, literacy, socioeconomic indicators, distance from pharmacy) can simulate adherence curves for chronic disease management. We have the biomarker data. We have the ontology. MiroFish gives us the simulation layer.

3. **Manchester Triage load prediction.** Emergency department overflow is one of Brazil's most acute healthcare crises. If we can simulate patient inflow patterns — using MiroFish-style agent populations conditioned on seasonal disease signals, local epidemiology, and calendar patterns — we can give hospital administrators a 72-hour prediction window for triage load. This is clinically high-value, evidence-supported, and does not cross the SaMD diagnostic boundary.

**What it CANNOT do without triggering my veto:**

- Individual patient prognosis presented as clinical recommendation. This requires human review, provenance metadata on every rule, and proper SaMD classification. The simulation is a supporting signal, never a standalone output.
- Any biomarker inference from simulated agents applied to real patients without validation study.
- Population predictions presented with confidence intervals we have not validated against historical data.

**The provenance requirement stands unconditionally:** every clinical output — even population-level — must carry `sourceAuthority` and `citationUrl`. MiroFish predictions are Tier 3 without ground-truth validation. We treat them as scenario exploration, not evidence.

*ELENA yields to RUTH.*

---

### SESSION 1.3 — REGULATORY LANDSCAPE

**[DELEGATING TO: RUTH — CLO & Regulatory Guardian]**

*RUTH opens her folder.*

The regulatory landscape in 2026 is more fragmented than it was 18 months ago, and that fragmentation is strategic opportunity for us if we navigate it correctly — and existential risk if we don't.

**FDA (US context, watching for export precedent):**

In April 2025, the FDA published a strategic roadmap endorsing AI-based computational models for preclinical safety. In January 2026, they launched a new policy era following the AI executive order. The direction is clear: they want AI in health, but they want it auditable, transparent, and with clear human-in-the-loop gates. Over 250 healthcare AI bills have been introduced across 34 US states. The regulatory velocity is high and inconsistent.

**ANVISA (Brazil — our primary jurisdiction):**

ANVISA classifies AI-based clinical tools under RDC 657/2022. Any software that influences clinical decision-making for individual patients is SaMD Class II or III depending on risk level. Population-level analytics and prediction tools — with appropriate disclaimers — can be classified as Class I or outside SaMD scope entirely. **This is our regulatory moat.** We build the simulation layer as population analytics, not individual diagnosis. That is not semantic gymnastics; it is proper clinical scope.

**LGPD (Brazilian Data Protection — my supreme concern):**

If MiroFish-style simulation is applied to real patient data:

1. We need granular consent for use of health data in population modeling — this is distinct from treatment consent and from research consent. We cannot collapse these into one checkbox. That is a hard veto.
2. Any cross-border transfer of patient data (e.g., to run simulation on a US-hosted LLM API) must satisfy LGPD Art. 33 adequacy requirements. We must evaluate whether Alibaba Qwen-Plus (MiroFish's default LLM) or any substituted model routes data outside Brazil. If it does, we need either a Brazilian-hosted inference endpoint or explicit adequacy documentation.
3. The `legalBasis` field is mandatory on every export or simulation initialization call that touches PHI.

**My recommendation:** Build the simulation pipeline on **fully synthetic, statistically representative patient profiles** generated from our population distributions. Real data trains the distributions; synthetic agents run the simulation. This satisfies LGPD, sidesteps SaMD classification, and still produces clinically meaningful predictions.

*RUTH yields. ARCHIE calls the day's first synthesis.*

---

### DAY 1 SYNTHESIS — ARCHIE

The board has now mapped the terrain. Let me crystallize what we've established:

**The opportunity is real and time-sensitive.** The $300B healthtech market is in structural transition from passive informatics to agentic health stewardship. LATAM is specifically underserved by the current wave of agentic tools. The white space is: prediction-driven clinical intelligence for the LATAM regulatory context.

**The MiroFish signal is actionable.** Not as a direct product integration, but as architectural inspiration. The five-stage pipeline (Graph Construction → Simulation → Report → Interaction) maps cleanly onto our existing CDSS stack if we think of our patient population as the "simulation environment" and our biomarker ontology as the "seed material."

**The constraints are clear and non-negotiable.** RUTH, ELENA, and CYRUS have drawn hard lines. Synthetic data for simulation. Population-level scope. Provenance on every clinical output. LGPD-compliant inference. These are not obstacles — they are our moat. Competitors who move fast and skip these constraints will face ANVISA enforcement. We build correctly and we build once.

**Day 2 goes deep on what to build.**

---

---

# DAY 2 — PRODUCT & ARCHITECTURE SPRINT
## "What we build next and how we build it"

---

### SESSION 2.1 — ARCHITECTURE PROPOSAL

**[ACTIVATING: ARCHIE — CTO & Principal Architect]**

*ARCHIE at the whiteboard.*

I'm proposing we build what I'll call **Cortex Swarm Layer (CSL)** — a simulation pipeline that sits alongside our existing CDSS kernel without touching the clinical decision logic. Here is the architecture:

```
┌─────────────────────────────────────────────────────────────────┐
│                     CORTEX SWARM LAYER (CSL)                    │
├──────────────────┬──────────────────┬───────────────────────────┤
│  SEED BUILDER    │   AGENT FACTORY  │     SIMULATION ENGINE     │
│                  │                  │                           │
│ • Pulls anonymized│ • Generates      │ • OASIS-compatible        │
│   population      │   synthetic      │   multi-agent runtime     │
│   distributions   │   patient agents │ • GraphRAG knowledge      │
│   from our DB     │   from stats     │   graph per simulation    │
│ • Extracts        │ • Each agent:    │ • Temporal memory per     │
│   biomarker       │   demographics,  │   agent (Zep-compatible)  │
│   patterns        │   comorbidities, │ • Parallel simulation     │
│ • Seasonal/       │   behavioral     │   runs (N=1000 default)   │
│   epidemiological │   profile,       │                           │
│   signals         │   adherence      │                           │
│                  │   propensity      │                           │
├──────────────────┴──────────────────┴───────────────────────────┤
│                      REPORT LAYER                               │
│  • ReportAgent generates population prediction summaries        │
│  • All outputs tagged: sourceAuthority="CSL-Simulation-v{n}"    │
│  • Confidence intervals from N simulation runs                  │
│  • NEVER individual patient output — population cohort only     │
├─────────────────────────────────────────────────────────────────┤
│                    INTEGRATION SURFACE                          │
│  • REST API → existing CDSS dashboard                          │
│  • Prediction widgets: 72h triage load, 30/90/180d cohort      │
│    deterioration risk, drug adherence simulation                │
│  • All calls: createProtectedRoute() + verifyPatientAccess()   │
└─────────────────────────────────────────────────────────────────┘
```

**Stack decisions:**

- **Simulation Runtime:** Python 3.11, OASIS framework (CAMEL-AI, open source, MIT-compatible). We fork and self-host — we do NOT route patient-derived data to external APIs.
- **LLM Inference:** Self-hosted Qwen or Llama 3.3 on our own infrastructure OR a Brazilian-hosted cloud endpoint. RUTH's LGPD Art. 33 constraint is non-negotiable on this point.
- **Memory Layer:** Zep-compatible interface, self-hosted, PHI never leaves our perimeter.
- **GraphRAG:** LlamaIndex or our own implementation — the graph encodes disease ontologies, drug interactions, demographic correlations. This is our proprietary IP.
- **Frontend:** New Vue.js module, consistent with existing architecture (41.1% of codebase is already Vue).
- **Data boundary:** Seed data generation pulls from our anonymized population distributions — **real patient records never enter the simulation runtime.**

**What this is NOT:**

- It is not a replacement for our clinical decision engine.
- It is not a diagnostic tool for individual patients.
- It is not an LLM answering clinical questions without provenance.

It is a **population intelligence instrument** that gives clinicians and hospital administrators a prediction window they don't currently have anywhere else in LATAM.

*ARCHIE delegates to PAUL for product surface design.*

---

### SESSION 2.2 — PRODUCT SURFACE & USER VALUE

**[ACTIVATING: PAUL — CPO & UX Strategist]**

*PAUL sketches rapidly.*

Thank you ARCHIE. Let me translate the architecture into user value — because the most elegant pipeline in the world is worthless if clinicians don't understand what they're looking at or trust what it tells them.

**Three product surfaces, in priority order:**

---

**Surface 1: Triage Load Predictor (TLP)**
*"How many patients are coming tomorrow?"*

This is the highest-urgency, lowest-regulatory-friction surface we can ship. Hospital administrators and ED chiefs want one thing: predictability. Manchester Triage overwhelm is Brazil's most visible healthcare systems failure.

The UI is a single dashboard widget — 72-hour rolling forecast of expected patient inflow by severity tier (P1-P5), with a confidence band. Inputs: local epidemiological signals, calendar (holidays, school terms), seasonal disease patterns, our historical triage data. Simulation: 1,000 synthetic patient-agent runs per forecast cycle.

Design principle: **no individual patient data on this screen ever.** It's a weather forecast for the ED. Clinicians understand weather forecasts. This is our Trojan horse into hospital enterprise contracts.

---

**Surface 2: Cohort Deterioration Risk Map (CDRM)**
*"Which of our chronic disease populations are at highest 90-day risk?"*

This surface targets the medical director and population health manager role. We visualize cohort-level risk clusters — diabetic patients with sub-optimal HbA1c trajectories, hypertensive patients with low adherence probability — aggregated from simulation runs over synthetic agent populations that mirror our real patient distributions.

The visualization: a risk matrix (likelihood × severity) with cohort segments represented as nodes. Drill-down shows which biomarker patterns are driving the simulation outcomes. The clinical team can then design proactive interventions.

Design principle: **no individual patient identified.** Minimum cohort size threshold (n≥20) before any display. ELENA will specify the provenance label requirements; RUTH will specify the consent disclosure language.

---

**Surface 3: Drug Adherence Simulation (DAS)**
*"Will this patient population actually take this medication?"*

This is the most complex surface and should ship 90 days after TLP. It requires integrating socioeconomic behavioral profiles into our agent factory. The value proposition: pharmaceutical companies doing outcomes-based contracting, and health plans managing chronic disease populations, will pay a significant premium for predicted adherence curves before they commit to a therapy rollout.

This surface also has the most interesting B2B2B sales motion (hospital → health plan → pharma), which VICTOR will cover in the next session.

**Cross-cutting UX principles for all three surfaces:**

- Every simulation output carries a visible "SIMULATION — Population Level" badge. No exceptions.
- Confidence interval displayed with every prediction. Users must see uncertainty, not false precision.
- "Explain this prediction" affordance on every major output — shows which agent behavioral patterns drove the result. This is how we build clinician trust.
- Full LGPD consent disclosure visible on first use of each surface. Ruth designs the consent language; I design the interaction flow.

*PAUL yields to VICTOR.*

---

### SESSION 2.3 — GO-TO-MARKET & PRICING

**[ACTIVATING: VICTOR — CSO & Enterprise Sales Director]**

*VICTOR leans forward.*

The product surfaces PAUL just described map to three distinct buyer types, three pricing models, and a sequenced GTM that I want to nail down here.

**Buyer Segment 1: Hospital Systems (TLP + CDRM)**

The ED Triage Load Predictor is a conversation-opener with hospital CFOs and medical directors. The value language is: "reduce unplanned ICU overflow by X%, reduce divert events by Y%." We tie pricing to bed-utilization improvement — outcome-linked SaaS at a base platform fee plus a performance bonus.

Entry price point: R$8,000–R$15,000/month per hospital facility. Upsell to CDRM at R$5,000/month incremental. This is modest enough to get through hospital procurement in one budget cycle. The market: Brazil has approximately 7,000 hospitals. We need 50 to cover our operating costs at scale.

**Buyer Segment 2: Health Plans & Insurers (CDRM + DAS)**

Health plans managing chronic disease populations are desperate for population risk stratification. They currently use actuarial models that are static, backward-looking, and don't account for behavioral adherence dynamics. Our Cohort Deterioration Risk Map + Drug Adherence Simulation gives them a forward-looking, simulation-grounded risk score.

Pricing: per-covered-life model. R$2–R$5 per member per month for the simulation intelligence layer. A health plan with 500,000 members generates R$1M–R$2.5M ARR for us. The top 10 health plans in Brazil each cover millions of lives. This is our scale path.

**Buyer Segment 3: Pharmaceutical (DAS)**

Pharma companies doing outcomes-based contracting in Brazil need adherence prediction at launch. A single Phase IV study costs them $10M–$50M. If our simulation can de-risk that study design, we can charge accordingly. Pricing model: project-based engagement, R$200K–R$500K per adherence simulation study.

**GTM Sequencing:**

1. **Months 1–6:** Pilot TLP with 3 anchor hospitals in São Paulo and Rio de Janeiro. Use pilot data to validate simulation accuracy against actual triage outcomes. This is our clinical validation story.
2. **Months 7–12:** Launch CDRM to health plan segment using pilot validation data as proof point. Sign 2–3 health plans.
3. **Months 13–18:** Launch DAS. Use health plan cohort data (anonymized, consented) to enrich agent behavioral profiles. Approach pharma with validated simulation methodology.

**Competitive moat language:**

"We are the only clinical intelligence platform in LATAM that predicts population health behavior through validated swarm simulation — built natively for LGPD compliance and ANVISA's regulatory framework." No one else can say that yet.

*VICTOR yields to GORDON.*

---

### SESSION 2.4 — UNIT ECONOMICS & RUNWAY ANALYSIS

**[ACTIVATING: GORDON — CFO & Unit Economics Analyst]**

*GORDON pulls up the numbers.*

I want to be the cold water here, because VICTOR's vision is compelling and I want it to succeed — which means it needs to be economically honest.

**The COGS problem with swarm simulation:**

MiroFish's biggest acknowledged limitation is compute cost. Each agent requires LLM API calls. 1,000 agents × 50 interaction rounds × 1 API call per interaction = 50,000 LLM calls per simulation run. At current inference pricing:

- GPT-4o equivalent: ~$0.005/1K tokens × 200 tokens/call = $0.001/call × 50,000 = **$50 per simulation run**
- Open-weight self-hosted (Llama 3.3 on our own GPU): ~$0.0001/call × 50,000 = **$5 per simulation run**

This is the difference between a product with 90% gross margin and one that hemorrhages money. RUTH has already ruled that LGPD compliance may require self-hosted inference anyway. That constraint and our COGS interest are aligned. **We must self-host.**

**Infrastructure investment:**

A meaningful self-hosted inference setup (4× A100 80GB or equivalent) runs approximately R$50,000–R$80,000/month in cloud or R$800,000–R$1.2M in owned hardware capex. At our current runway, I recommend cloud-first (R$50K/month) until we hit 10 paying hospital customers, then evaluate owned hardware.

**The unit economics at target scale:**

| Segment | ACV | Marginal COGS (compute) | Gross Margin |
|---------|-----|------------------------|--------------|
| Hospital (TLP) | R$120K/year | R$8K/year | ~93% |
| Health Plan (CDRM) | R$600K–R$1.5M/year | R$30K/year | ~95–98% |
| Pharma (DAS) | R$250K–R$500K/project | R$15K/project | ~94–97% |

Those margins are exceptional **if** we self-host inference. They collapse to 40–60% margins if we pay API pricing. This is a non-negotiable architectural decision, not a preference.

**Runway impact:**

Adding the Cortex Swarm Layer adds approximately R$50K/month in compute costs before we have paying customers. At pilot scale (3 hospitals free pilots), that is R$150K burn before first revenue. I recommend: cap the free pilot period at 90 days and price pilot access at a nominal R$1,500/month to cover bare compute. This also signals market value and filters committed buyers.

*GORDON yields. ARCHIE holds for CYRUS and RUTH on security and compliance architecture.*

---

### SESSION 2.5 — SECURITY ARCHITECTURE FOR SIMULATION

**[ACTIVATING: CYRUS — CISO & Security Architect]**

*CYRUS speaks quietly but with weight.*

I have three hard requirements and one recommendation for how we architect the Cortex Swarm Layer.

**Hard Requirement 1: Agent isolation per tenant.**

Every simulation run is tenant-scoped. An agent factory spun up for Hospital A cannot reference any data — even synthetic — that was derived from Hospital B's population. This means simulation runs execute in isolated containers with tenant-namespaced seed data. Cross-tenant contamination is not a performance optimization target; it is a security violation under our existing RBAC architecture. `verifyPatientAccess()` must gate every seed data generation call.

**Hard Requirement 2: PHI never enters the simulation runtime.**

The synthetic agent generation pipeline must operate as follows: real PHI → anonymization/distribution extraction layer → statistical profile → synthetic agent. At no point does a CPF, CNS, or RG number appear in agent memory, agent persona, or simulation graph. The anonymization layer must use `encryptPHIWithVersion` on any intermediate representation before statistical aggregation. The agents themselves are probabilistic constructs, not pseudonymized real patients.

**Hard Requirement 3: Audit trail for simulation calls.**

Every simulation initiation, every seed data generation call, every report output must write to our existing `AuditLog` with the standard hash-chain integrity. If a hospital later asks "what data was used to generate this triage prediction on March 17," we can produce a complete, tamper-evident audit trail. The AuditLog records are retained per LGPD Art. 37 — they are never destroyed, including for simulation metadata.

**Recommendation: Air-gap the simulation runtime from the clinical CDSS kernel.**

The CDSS clinical decision engine and the Cortex Swarm Layer should run in separate network segments. The CSL makes calls to the CDSS read-only API to fetch population distributions; it never writes back to clinical records. Bidirectional data flow between prediction layer and clinical layer is a lateral attack surface. Uni-directional: CSL reads anonymized distributions from CDSS, CSL writes prediction reports to a separate prediction data store. The prediction data store is accessible to dashboard and reporting services; it is not accessible from the clinical kernel.

*CYRUS yields to QUINN.*

---

### SESSION 2.6 — VALIDATION & QUALITY GATES

**[ACTIVATING: QUINN — QA Lead & Test Automation]**

*QUINN methodical, focused.*

Agentic and simulation systems are a fundamentally new testing challenge. I want to establish the quality gates before we write a single line of simulation code.

**Testing categories for the Cortex Swarm Layer:**

**Category 1: Determinism tests.**
Given the same seed data and same random seed, simulation runs must produce consistent distribution outputs within acceptable variance bounds. We cannot have a system that gives a hospital 40 predicted P2 patients today and 120 tomorrow with no change in inputs. Acceptable variance: ±15% on predicted counts for identical seed conditions. This is testable.

**Category 2: Boundary tests on agent generation.**
Every agent must pass a schema validation test: does it have required fields (demographics, comorbidities, behavioral profile, no PHI identifiers)? We run automated schema validation on 100% of generated agents before simulation execution.

**Category 3: Population fidelity tests.**
The synthetic agent population must statistically mirror the real population distribution on key dimensions (age distribution, comorbidity prevalence, geographic distribution). Chi-squared tests run automatically on each population generation. If p < 0.05 (significant divergence from real population), generation fails with a hard error — not a warning.

**Category 4: Output provenance tests.**
Every simulation report output is tested for presence of required provenance metadata: `sourceAuthority`, `simulationRunId`, `agentCount`, `simulationVersion`, `legalBasis`. Missing fields fail CI. This is ELENA's requirement and RUTH's requirement translated into an automated gate.

**Category 5: Latency and circuit-breaker tests.**
Individual simulation runs should complete within configurable time bounds. If a simulation run exceeds 5× expected duration, the circuit breaker trips and the run is terminated. We do not allow runaway simulation jobs to exhaust compute or delay clinical dashboard loads.

**CI integration:**
All five categories run in our existing Jest/pytest CI pipeline. No simulation code merges without passing all five. ARCHIE, you need to provision a simulation test environment with a small synthetic population (N=100 agents) for fast CI runs.

---

### DAY 2 SYNTHESIS — ARCHIE

*End of Day 2 session. 1900h.*

We have built the product and architecture blueprint. Summary of Day 2 decisions:

**What we're building:**
1. Cortex Swarm Layer (CSL) — population simulation engine on OASIS framework, self-hosted inference, tenant-isolated, air-gapped from clinical kernel.
2. Three product surfaces: Triage Load Predictor (TLP), Cohort Deterioration Risk Map (CDRM), Drug Adherence Simulation (DAS) — in that sequence.
3. GraphRAG knowledge graph encoding our disease ontologies, biomarker correlations, and drug interaction data as the proprietary intelligence layer.

**Non-negotiables confirmed by veto seat holders:**
- RUTH: Synthetic data only in simulation. LGPD granular consent. Self-hosted LLM. `legalBasis` on every call.
- ELENA: Population scope only. Provenance metadata on every output. Simulation results are Tier 3 without validation study.
- CYRUS: Tenant isolation. PHI air-gap. Audit trail on every simulation call. Uni-directional data flow.
- QUINN: Five-category automated test suite. All gates in CI before merge.

**GTM plan confirmed:**
- Phase 1 (months 1–6): 3 hospital pilots for TLP.
- Phase 2 (months 7–12): Health plan CDRM launch.
- Phase 3 (months 13–18): Pharma DAS engagement.

---

---

# DAY 3 — EXECUTION PRIORITIES & SPRINT SEQUENCING
## "What gets built in Q2 2026 — and in what order"

---

### SESSION 3.1 — IMMEDIATE CODE PRIORITIES

**[ACTIVATING: ARCHIE — CTO & Principal Architect]**

*ARCHIE opens with the sprint roadmap.*

Day 3 is about execution. We translate three days of thinking into a prioritized backlog that the engineering team can execute immediately. I will propose the order; each seat will challenge or confirm.

**Tier 1 — Foundational Infrastructure (Weeks 1–4)**

These are prerequisites. Nothing in Tier 2 or 3 is possible without them.

1. **Provision self-hosted LLM inference endpoint.** Evaluate Llama 3.3 70B vs Qwen 2.5 72B on a 4×A100 cluster. Benchmark: inference speed for 200-token agent interactions at 1,000 concurrent agents. GORDON approves capex. RUTH validates LGPD residency. CYRUS validates network isolation.

2. **Build synthetic patient profile generator.** Input: anonymized population distributions from our existing CDSS patient database. Output: JSON agent profiles conforming to our schema (demographics, comorbidities, behavioral parameters, NO PHI). QUINN writes schema validation tests first (test-driven). ELENA validates that generated profiles are clinically plausible (no impossible biomarker combinations).

3. **Fork and adapt OASIS framework.** Remove social media-specific logic (Twitter/Reddit actions). Replace with clinical interaction model (triage presentation, medication adherence action, symptom escalation action, care-seeking behavior). ARCHIE owns this. ELENA reviews clinical action model. CYRUS reviews that agent-to-agent interaction logs contain no PHI.

4. **Audit trail extension for simulation.** Add `SimulationRun` model to our schema. Every run: `runId`, `tenantId`, `agentCount`, `seedVersion`, `legalBasis`, `initiatedBy`, `outputHash`. Hash-chain integrity per existing AuditLog protocol. QUINN writes audit trail tests. CYRUS reviews schema.

**Tier 2 — First Product Surface (Weeks 5–10)**

5. **Build GraphRAG knowledge graph for triage prediction.** Seed data: last 24 months of Manchester Triage records (anonymized), seasonal disease prevalence from Brazilian DATASUS, local hospital admission patterns. Graph entities: disease, symptom, severity, season, geography. Edges: temporal correlations. ARCHIE implements. ELENA validates ontological correctness.

6. **Build Triage Load Predictor simulation pipeline.** Runs N=1,000 synthetic patient-agents through a 72-hour time window. Agents present to triage probabilistically based on their profile and the environmental signals. Output: distribution of expected P1–P5 arrivals per 8-hour window. ARCHIE implements simulation. PAUL designs output schema for dashboard consumption.

7. **Build TLP dashboard widget.** Vue.js component. Shows 72h forecast with confidence bands by severity tier. "Explain this prediction" button triggers a drill-down of the agent behavioral patterns driving the outcome. PAUL owns UX. QUINN writes component tests. Full `createProtectedRoute` guard — hospital admin role only.

**Tier 3 — Second Product Surface (Weeks 11–20)**

8. **Cohort Deterioration Risk Map** — agent behavioral profiles extended with chronic disease management parameters (HbA1c trajectory, antihypertensive adherence propensity, care-seeking frequency). Simulation over 30/90/180-day windows. Output: risk matrix visualization with cohort segments. PAUL designs; ELENA reviews clinical logic; RUTH reviews population consent language.

9. **Health Plan API** — programmatic access to CDRM for health plan partner integrations. REST API with tenant-scoped auth, rate limiting, and per-call audit logging. VICTOR finalizes commercial terms for API pricing. CYRUS reviews auth architecture.

**Tier 4 — Third Product Surface (Months 6+)**

10. **Drug Adherence Simulation** — requires behavioral economics parameters in agent model (health literacy, socioeconomic proxy, distance-to-pharmacy, prior adherence history from anonymized claims). ELENA specifies clinical requirements. VICTOR drives pharma GTM simultaneously.

---

### SESSION 3.2 — PRODUCT CHALLENGES TO ARCHIE'S SPRINT PLAN

**[ACTIVATING: PAUL — CPO & UX Strategist]**

I want to add one item to Tier 1 that ARCHIE didn't include and I consider equally critical:

**User trust architecture.** Before we show a clinician a simulation-derived prediction, we need a trust calibration study. We need to understand: how do emergency physicians, medical directors, and hospital administrators mentally model a "swarm simulation prediction"? Do they understand it is not an individual patient diagnosis? Do they trust it appropriately — not too much, not too little?

I'm proposing we run a 3-week user research sprint in parallel with Tier 1 infrastructure. We recruit 10–15 clinical informatics users from our existing customer base, show them mockups of the TLP widget with different explanatory framings, and measure comprehension and trust calibration. This research informs the final UI copy, the level of explanatory detail, and the disclosure language RUTH needs to approve.

This is not a luxury. Misplaced clinical trust in a simulation tool is an ELENA and RUTH veto-level risk. We build the trust architecture before we ship the interface, not after.

*PAUL yields. ELENA affirms.*

---

**[ACTIVATING: ELENA — CMO & Clinical Evidence Guardian]**

PAUL is correct and I want to strengthen his point. The "Explain this prediction" affordance PAUL specified in the TLP widget is not just UX polish — it is a clinical safety requirement. Every clinician using the Triage Load Predictor must be able to see: "This prediction is based on a simulation of 1,000 synthetic patient agents derived from your hospital's historical triage patterns. It is not a diagnosis. It does not reflect individual patient data. Accuracy against historical data: [validation metric]."

That last field — accuracy against historical data — means we need our pilot period to generate validation data. For the first 90 days of each pilot, we run the simulation and we record the predictions, but we also record the actual outcomes. At the end of 90 days, we publish an internal validation report: predicted vs actual triage load, MAPE, calibration curve.

This validation data becomes two things simultaneously: ELENA's clinical evidence requirement for progressing beyond pilot, and VICTOR's sales proof point for the health plan expansion. One data collection effort, dual strategic value.

---

### SESSION 3.3 — REGULATORY SPRINT PLAN

**[ACTIVATING: RUTH — CLO & Regulatory Guardian]**

The legal and compliance sprint runs in parallel with product development. Here is what I need completed in Q2 2026:

**Week 1–2: Data Classification Memo**
Define precisely what data is used to train population distributions (real, PHI-adjacent, requires full LGPD treatment) versus what data enters the simulation runtime (synthetic, no LGPD scope). This memo becomes the foundation of our compliance documentation and our answer if ANVISA ever asks.

**Week 2–4: Consent Architecture Design**
Work with PAUL to design granular consent flows for three distinct purposes:
1. Treatment consent (existing)
2. Population research consent (anonymized data used to train statistical distributions)
3. Prediction service consent (results from simulation used in clinical workflow planning)

These are three separate consent types. They may be presented in a single session but must be individually toggleable and individually revocable.

**Week 4–6: ANVISA Classification Analysis**
Formal internal memo on whether TLP, CDRM, and DAS fall within SaMD scope under RDC 657/2022. My preliminary analysis: TLP is out of SaMD scope (population analytics, no individual patient clinical decision influence). CDRM is borderline (must include explicit "not for individual patient use" disclaimers). DAS may require Class I SaMD registration depending on how pharma clients use the output.

**Week 6–8: LLM Vendor Legal Review**
Review data processing agreements for our self-hosted inference choice. Confirm: (1) model weights are on Brazilian soil or in an LGPD-adequate jurisdiction, (2) no training data retention from our inference calls, (3) standard contractual clauses in place for any residual transfer risk.

**Ongoing: LGPD Art. 37 Audit Log Verification**
CYRUS and I will conduct monthly joint reviews of the simulation audit log to confirm hash-chain integrity, retention compliance, and no inadvertent PHI leakage into simulation records.

---

### SESSION 3.4 — THE BIGGER PICTURE

**[ACTIVATING: VICTOR — CSO & Enterprise Sales Director]**

Before we close, I want to zoom out to the 18-month picture. Because the Cortex Swarm Layer is not just a product feature — it is a **company-defining strategic repositioning.**

**Right now, we are:** a CDSS platform with biomarker tracking, Manchester triage logic, and patient data management. That is valuable. It is also becoming commoditized by the ambient AI wave.

**In 18 months, with CSL, we are:** the only platform in LATAM that closes the loop between historical clinical data, real-time biomarker tracking, and predictive population simulation. We are not a documentation tool or a decision support layer. We are a **clinical operating intelligence system** — one that tells hospital systems not just what is happening with patients, but what is about to happen with populations.

The competitive moat has three reinforcing components:
1. **Data moat:** Our historical patient population data trains richer, more accurate simulation agents than any competitor who starts from scratch.
2. **Regulatory moat:** Our LGPD/ANVISA-native architecture is a 12–18 month head start on any US or European competitor entering LATAM.
3. **Validation moat:** Every pilot generates ground-truth validation data that improves our simulation accuracy. The system gets smarter as we scale. This is a flywheel.

The companies that will try to enter this space in LATAM: Epic (too slow, US-centric), Microsoft/Nuance (documentation-focused, not prediction-focused), Hippocratic AI (consumer health, different scope), Qure.ai (imaging-specific). None of them are building what we're building in this market.

We have a 12-month window of clear blue water. We must use it.

---

### SESSION 3.5 — FINAL SECURITY POSTURE

**[ACTIVATING: CYRUS — CISO & Security Architect]**

Three additions to the execution plan that do not appear anywhere yet and must:

**1. Simulation Abuse Prevention**

A simulation engine that takes seed data as input is potentially a data exfiltration vector. A malicious actor with hospital admin credentials could craft seed data that encodes real patient information into agent profiles and then extract it via simulation outputs. We prevent this by: schema enforcement on agent profiles (no free-text fields that could carry PHI), output sanitization layer (ReportAgent outputs are scanned for patterns matching CPF/CNS/RG formats before return), and anomaly detection on simulation initiation requests (flag any seed data that deviates significantly from expected population distributions).

**2. Model Poisoning Prevention**

When we use real population distributions to calibrate our synthetic agent generator, that calibration model is a potential attack surface. If adversarial data enters our patient database, it could bias the agent generator toward producing predictions that benefit a bad actor. Mitigation: the calibration model is retrained on a versioned, audited snapshot of patient data — never on live, unreviewed data. Each calibration snapshot is signed and its hash recorded in the AuditLog.

**3. Simulation-to-Clinical Firewall**

ARCHIE's architecture already calls for uni-directional data flow (CSL reads from CDSS, never writes). I want this enforced at the network layer, not just the application layer. The simulation service account has database READ-ONLY permissions on anonymized population tables. It has WRITE access only to the prediction data store. Any attempt to write to clinical tables from the simulation service generates a security alert and is automatically rejected at the DB level.

These three measures are not optional features. They ship with the first line of simulation code.

---

### SUMMIT CLOSING — ARCHIE

*Day 3. 1730h. All eight seats present.*

We have spent three days doing something rare: thinking clearly about an inflection point before it arrives rather than scrambling to respond after it has passed.

MiroFish is the signal that swarm simulation has crossed the economic viability threshold. The OASIS framework, open-source and scalable to one million agents, is available to us today. Our biomarker ontology, our clinical knowledge graph, our historical population data, and our LATAM regulatory expertise are available to no competitor today.

The synthesis of what we've decided:

**We will build the Cortex Swarm Layer** — a population simulation engine that transforms our CDSS from a reactive data platform into a predictive clinical operating intelligence system.

**We will build it correctly** — LGPD-compliant, ANVISA-appropriate, CYRUS-hardened, ELENA-validated, with QUINN's quality gates enforced from the first commit.

**We will build it strategically** — VICTOR's three-phase GTM, GORDON's self-hosted compute economics, PAUL's trust-calibrated UX.

**The 18-month vision:** We are the first platform in Latin America where a hospital administrator opens their dashboard at 7am and sees — with calibrated confidence — what their ED will look like at 7pm. Where a health plan's medical director sees which of their 500,000 members will deteriorate in the next 90 days before a single clinical event occurs. Where a pharma company knows the adherence curve for a new therapy before they run a single patient through a trial.

That is the company we are building. This summit has mapped the path.

**ARCHIE calls the session adjourned.**

---

---

## SUMMIT DECISIONS REGISTER

| # | Decision | Owner | Target Date | Veto Seat Confirmed |
|---|----------|-------|-------------|---------------------|
| 1 | Self-host LLM inference (LGPD + COGS requirement) | ARCHIE + GORDON | Week 2 | RUTH ✓ |
| 2 | Synthetic-only data in simulation runtime | ARCHIE + CYRUS | Architecture spec, Week 1 | RUTH ✓, CYRUS ✓ |
| 3 | Population-scope only (no individual patient prediction) | PAUL + ELENA | UX spec, Week 2 | ELENA ✓, RUTH ✓ |
| 4 | Provenance metadata on all simulation outputs | ARCHIE + QUINN | CI gate, Week 3 | ELENA ✓ |
| 5 | Uni-directional data flow CSL → prediction store only | CYRUS | Architecture spec, Week 1 | CYRUS ✓ |
| 6 | Granular consent (3 distinct types) | RUTH + PAUL | Design sprint, Week 3 | RUTH ✓ |
| 7 | 90-day pilot validation protocol | ELENA + VICTOR | Pilot agreement, pre-launch | ELENA ✓ |
| 8 | ANVISA classification memo for TLP/CDRM/DAS | RUTH | Week 6 | RUTH ✓ |
| 9 | Simulation abuse prevention + firewall | CYRUS | Pre-production | CYRUS ✓ |
| 10 | User trust research sprint | PAUL | Weeks 1–3 (parallel) | — |
| 11 | GTM Phase 1: 3 hospital pilots (São Paulo, Rio) | VICTOR | Month 1 | — |
| 12 | Compute capex: cloud-first until 10 customers | GORDON | Pre-launch | GORDON ✓ |

---

## OPEN QUESTIONS FOR FOLLOW-UP

1. **Which Brazilian cloud provider** satisfies LGPD residency requirements and can host OASIS at the required inference throughput? (ARCHIE + RUTH — due Week 1)
2. **Which 3 pilot hospitals** are ready for a TLP pilot? Do we have existing relationships sufficient to execute within 30 days? (VICTOR — due Week 2)
3. **Calibration model versioning strategy** — do we use MLflow or a custom versioning approach for the agent generator calibration snapshots? (ARCHIE + CYRUS — due Week 3)
4. **ELENA's validation threshold** — what is the minimum acceptable MAPE for TLP before we allow commercial deployment beyond pilot? (ELENA — due Week 4)
5. **MiroFish license review** — the MIT-licensed OASIS framework is the simulation engine. Do we need a separate contribution agreement if we fork for clinical use? (RUTH — due Week 1)

---

## BOARD MEETING FORMAT — FINAL POSITIONS

> *Per CLAUDE.md: 3+ agents activated → Board Meeting format required.*

| Seat | Position Summary |
|------|-----------------|
| ARCHIE | Build CSL on OASIS; self-host inference; air-gap architecture; Tier 1 infrastructure is the critical path. |
| PAUL | Three product surfaces in sequence; trust calibration research before UX ships; "Explain this prediction" is non-negotiable. |
| VICTOR | 12-month competitive window; three-buyer GTM; outcome-linked pricing changes our category positioning entirely. |
| GORDON | Self-host or die on margins; cloud-first until 10 customers; nominal pilot pricing to cover compute. |
| RUTH | Synthetic data only; granular consent; ANVISA memo Week 6; LGPD residency confirmed before first inference call. |
| ELENA | Population scope enforced; 90-day validation protocol; provenance on all outputs; simulation is Tier 3 until validated. |
| CYRUS | Tenant isolation; PHI air-gap; simulation firewall at DB level; model poisoning prevention from day one. |
| QUINN | Five-category test suite; schema validation on 100% of agents; all gates in CI; no simulation code merges without full coverage. |

**Consensus achieved.** No vetoes in the final positions. The board is aligned.

---

*Document classification: Board Eyes Only — Cortex Boardroom Summit, March 17–19, 2026*
*Facilitator: ARCHIE | Protocol: KERNEL_V2 | Router: ROUTER.md*

---

### Sources Consulted

- [MiroFish — GitHub Repository](https://github.com/666ghj/MiroFish)
- [MiroFish: GitHub's #1 Trending AI Swarm Engine Hits 28K Stars](https://byteiota.com/mirofish-githubs-1-trending-ai-swarm-engine-hits-28k-stars/)
- [OASIS: Open Agent Social Interaction Simulations — CAMEL-AI](https://github.com/camel-ai/oasis)
- [Swarm Intelligence Market to Record USD 7.23 Billion by 2032](https://www.globenewswire.com/news-release/2026/02/25/3244336/0/en/Swarm-Intelligence-Market-to-Record-USD-7-23-Billion-by-2032-Exhibiting-a-Remarkable-CAGR-of-41.20-Driven-by-Rapid-AI-Adoption-and-Autonomous-System-Deployment-AnalystView-Market-I.html)
- [The 2026 Convergence: Big Tech, Agentic AI and the Restructuring of the Global HealthTech Ecosystem](https://www.healthcare.digital/single-post/the-2026-convergence-big-tech-agentic-ai-and-the-restructuring-of-the-global-healthtech-ecosystem)
- [State of Health AI 2026 — Bessemer Venture Partners](https://www.bvp.com/atlas/state-of-health-ai-2026)
- [How AI Agents and Tech Will Transform Health Care in 2026 — BCG](https://www.bcg.com/publications/2026/how-ai-agents-will-transform-health-care)
- [Latin America Healthtech Market Growth & Innovation 2025](https://www.towardshealthcare.com/news/latin-america-healthtech-growth)
- [MiroFish: The Open-Source AI Engine That Builds Digital Worlds to Predict the Future — DEV Community](https://dev.to/arshtechpro/mirofish-the-open-source-ai-engine-that-builds-digital-worlds-to-predict-the-future-ki8)
- [Swarm Intelligence Comes to Forecasting: How MiroFish Simulates What Happens Next — LinkedIn](https://www.linkedin.com/pulse/swarm-intelligence-comes-forecasting-how-mirofish-simulates-borish-lahve)
- [2026 Healthcare Predictions: AI, Blockchain, and the Rise of Decentralized Innovation — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12860439/)
- [Many Health Care Leaders Are Leaning into Agentic AI — Deloitte](https://www.deloitte.com/us/en/insights/industry/health-care/agentic-ai-health-care-operating-model-change.html)
- [Top AI Agent Companies in Healthcare 2026 — Keragon](https://www.keragon.com/blog/ai-agent-companies)
